BNGO — BioNano Genomics Income Statement
0.000.00%
Last trade - 00:00- $12.93m
- $7.25m
- $30.78m
Annual income statement for BioNano Genomics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 8.5 | 18 | 27.8 | 36.1 | 30.8 |
| Cost of Revenue | |||||
| Gross Profit | 2.77 | 3.87 | 5.95 | 9.57 | 0.38 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 47.1 | 95.4 | 160 | 251 | 135 |
| Operating Profit | -38.6 | -77.4 | -132 | -215 | -104 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -41.1 | -78.2 | -131 | -232 | -112 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -41.1 | -72.4 | -133 | -232 | -112 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -41.1 | -72.4 | -133 | -232 | -112 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -41.1 | -72.4 | -133 | -232 | -112 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -3.85 | -2.57 | -4.54 | -5.34 | -74 |